X @Bloomberg
Bloomberg·2025-08-12 16:08
If Novo's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen's CEO Chris Viehbacher doesn’t see it as a roadblock for his company’s medication https://t.co/3Und5Ww0w2 ...